Evidence map›Paper›PMID 25243629›Full record

Trial reportBone marrow transplantation2015

Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation.

A Israyelyan, L Goldstein, W Tsai, L Aquino, S J Forman, R Nakamura, D J Diamond

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Early Peripheral BloodInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

A IsrayelyanDivision of Translational Vaccine Research, Beckman Research Institute of City of Hope, Duarte, CA, USA.
L GoldsteinDivision of Biostatistics, Department of Information Sciences, Duarte, CA, USA.
W TsaiDepartment of Hematology/Hematopoietic Cell Transplantation, Duarte, CA, USA.
L AquinoClinical Trials Office, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
S J FormanDepartment of Hematology/Hematopoietic Cell Transplantation, Duarte, CA, USA.
R NakamuraDepartment of Hematology/Hematopoietic Cell Transplantation, Duarte, CA, USA.
D J DiamondDivision of Translational Vaccine Research, Beckman Research Institute of City of Hope, Duarte, CA, USA.
City of Hope · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Vaccine-Induced Immunity to CMVP01CA030206 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI BHATIA, SMITA · 1985 to 2010
$31.8M
Peptide Vaccine To Prevent CMV Disease After HSCTR01CA077544 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI DIAMOND, DON J · 1998 to 2017
$5.6M
NCI NIH HHS CA030206NCI NIH HHS CA077544NCI NIH HHS CA33572NCI NIH HHS P01 CA030206NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA077544
6 · The paper itself

Abstract

Relapse is the major cause of treatment failure after allogeneic hematopoietic cell transplantation (alloHCT) for acute leukemia and myelodysplastic syndrome (MDS). Wilms' tumor Ag (WT1) is overexpressed in the majority of acute leukemia and MDS patients and has been proposed as a universal diagnostic marker for detection of impending relapse. Comprehensive studies have shown that WT1 transcript levels have predictive value in acute leukemia patients in CR after chemotherapy. However, the focus of this study is the period after alloHCT for predicting relapse onset. We analyzed the accumulation of WT1 mRNA transcripts in PB of 82 leukemia and MDS patients and defined specific molecular ratios for relapse prediction. The extensively validated WT1/c-ABL ratio was used to normalize increases in WT1 transcript levels. The observed lead time of crossing or exceeding set WT1 levels is presented along with linear interpolation to estimate the calculated day the WT1 thresholds were crossed. The WT1/c-ABL transcript ratio of 50 or above yielded 100% specificity and 75% sensitivity reliably predicting future relapse with an observed average of 29.4 days (s.d.=19.8) and a calculated average of 63 days (s.d.=29.3) lead time before morphologic confirmation. A lower ratio of 20 or above gave lower specificity, but higher sensitivity (84.8% and 87.5%, respectively) identified more patients who relapsed, at earlier times, providing an earlier warning with actual average lead time of 49.1 days (s.d.=30.8) and calculated average of 78 days (s.d.=28.8). WT1 transcript levels serve as a diagnostic relapse test with greater sensitivity than the morphologic approach used in the clinic as a readout.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemiaMyelodysplastic SyndromesAcute DiseaseAdultAgedAllograftsBiomarkers, TumorFemaleHumansMaleMiddle AgedProto-Oncogene Proteins c-ablRecurrenceRisk FactorsRNA, MessengerBiomarkers, TumorProto-Oncogene Proteins c-ablRNA, MessengerRNA, NeoplasmWT1 protein, humanWT1 Proteins

Identifiers

PMID25243629
PMCPMC4286541
OpenAlexW2077034375

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.